Generics 17

Originals

Biosimilars

Medical devices

Nutraceuticals

Filters

Lenvatinib manufacturers

17 products found

Filters

17 products found

lenvatinib

Capsules 4 mg, 10 mg

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
European Union
GMP approvals
EU GMP
Comments
Western EU SPC Expiry: 19 Oct 2026
Manufacturer #276

Manufacturer usually replies in 1 days

lenvatinib

Capsules 4 mg , 10 mg

Dossier type
EU CTD
Dossier status
Under development
Country of origin
European Union
GMP approvals
EU GMP
Manufacturer #11907
A pharmaceutical manufacturer based in the EU that is active in 40+ countries selling its products for 20+ years. Key production lines include Rx, OTC, medical devices, and cosmetics. The company's production lines are EU GMP-compliant. The company owns branches in the EU, North America, and Africa.

Manufacturer usually replies in 8 days

lenvatinib

Capsules, hard liquid 4 mg, 10 mg

Dossier type
EU CTD
Dossier status
Under development
Country of origin
European Union
GMP approvals
EU GMP
Manufacturer #21467

Manufacturer usually replies in 9 days

lenvatinib

Capsules 4 mg, 10 mg

Dossier type
EU CTD
Dossier status
Under development
Country of origin
European Union
GMP approvals
EU GMP
Comments
Indication: Renal Cell Carcinoma; Status: Q1 2025 Under Development
Manufacturer #385

A pharmaceutical manufacturer based in the EU that has been active in 60+ countries selling its products in Europe, North America, LATAM, MENA, Africa, and Asia for 60+ years. Key production lines are Rx and nutraceuticals. The company's production lines are EU GMP-compliant.

Manufacturer usually replies in 11 days

lenvatinib

Oral suspension 4 mg/ml

Dossier type
EU CTD
Dossier status
Under development
Country of origin
European Union
GMP approvals
EU GMP
Manufacturer #31060

Manufacturer usually replies in nan days

lenvatinib

Capsules 4 mg, 10 mg

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
EU GMP
Unavailable markets
Costa Rica
Manufacturer #1338

Manufacturer usually replies in 7 days

lenvatinib

Capsules 4 mg, 10 mg

Dossier type
CTD
Dossier status
Under development
Country of origin
Canada
GMP approvals
Canada
Comments
Reference product : Lenvima (Eisai)
Manufacturer #278

The company has become a prominent partner of the pharmacy community in North America, with the fastest rising market share among generic leaders. It can provide best-in-class supply reliability thanks to production capacity. In more than 50 countries, it's available locally or through corporate partnerships. R&D expenditures range from $40 million to $50 million per year. They are dedicated to maintaining a customer satisfaction rate of over 95% by continuously enhancing supply chain efficiency.

Manufacturer usually replies in 7 days

lenvatinib

Capsules 4 mg, 10 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
EU GMP
Unavailable markets
Vietnam
Manufacturer #9406

Manufacturer usually replies in 7 days

lenvatinib

Capsules 4 mg , 10 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
Bangladesh
GMP approvals
WHO
Manufacturer #21024

Manufacturer usually replies in 2 days

lenvatinib

Capsules 4 mg , 10 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
Bangladesh
GMP approvals
WHO
Manufacturer #16099

Manufacturer usually replies in 6 days

lenvatinib

Capsules 4 mg, 10 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
WHO
Manufacturer #30013

Manufacturer usually replies in 2 days

lenvatinib

Capsules 4mg, 10mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
Argentina
GMP approvals
Argentina, Brazil, Pakistan, Paraguay, Peru, Uruguay, WHO, PICS
Unavailable markets
Argentina , Brazil , Chile , Ecuador , Paraguay , Peru , Uruguay
Manufacturer #16112

Manufacturer usually replies in 6 days

lenvatinib

Capsules 4 mg, 10 mg

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
FDA, EU GMP, WHO, MHRA
Manufacturer #16394

Manufacturer usually replies in 12 days

lenvatinib

Capsules 4 mg, 10 mg

Dossier type
US CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
FDA, Canada
Manufacturer #16394

Manufacturer usually replies in 12 days

lenvatinib

Capsules 4 mg, 10 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
Argentina
GMP approvals
PICS
Manufacturer #15733
One of the leading manufacturers in cosmetic and medicinal products in the South American Continent. The company has been committed since 1990-is to developing and manufacturing high-quality products that allow healing and improve someone’s life. They are a major exporter of its therapies to different regions such as Latin America and Asia. Medicine is manufactured for pain, gastroenterology, hepatology, and cardiology.

Manufacturer usually replies in 17 days

lenvatinib

Capsules 4 mg, 10 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
WHO
Manufacturer #32972

lenvatinib

Capsules 10 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
WHO
Manufacturer #30830

Lenvatinib Manufacturers

Lenvatinib is a member of the class of quinolones and belongs to a class of medication called kinase inhibitors. Lenvatinib is a multi-kinase inhibitor and orphan drug used for the treatment of various (progressive and differentiated) types of thyroid cancer that have returned or that have spread to other parts of the body and cannot be treated with radioactive iodine. Lenvatinib is the first-line treatment of unresectable hepatocellular carcinoma (HCC; a type of liver cancer) that cannot be treated with surgery. Lenvatinib is also used along with pembrolizumab (Keytruda) to treat a certain type of cancer of the endometrium (lining of the uterus) that has spread to other parts of the body or worsened during or after treatment with chemotherapy medications or that cannot be treated with surgery or radiation therapy. Lenvatinib is also used along with Everolimus to treat renal cell carcinoma in people who have previously received treatment with another chemotherapy medication. Lenvatinib is advised as a prescription product as well as the mixture product which is available only with the physician’s prescription. Lenvatinib is marketed by manufacturers under the Brand name Lenvima.

How does Lenvatinib work?

Lenvatinib is a receptor tyrosine kinase inhibitor that inhibits the kinase activities of vascular endothelial growth factor receptors. Lenvatinib also inhibits other receptor tyrosine kinase that has been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions including fibroblast growth factor receptors and the platelet-derived growth factor receptor. This drug is available in Capsule form which is administered orally with or without food. Lenvima is available in 4 mg and 10 mg dosage strengths. The 4 mg capsules have a yellowish-red body and yellowish-red cap and the 10 mg capsules have a yellow body and yellowish-red cap. Both the dosage strengths are marked in black ink with “Є” on the cap and “LENV 4 mg” / “LENV 10 mg” on the body.

The Cost of Lenvatinib

An online search for the wholesale price for sale of Lenvatinib for distributors will reveal a wide range of costs. It will vary from store to store depending on your visit and the country of the wholesale market. Wholesale Price of Lenvatinib In the USA, the wholesale cost for Lenvatinib 4 mg and 10mg oral capsules is around $19,867.42 for a supply of 30 capsules and the per-unit price comes at $ 662.25 depending on the pharmacy one visit. There is no change in the cost $ 19,867.42 for a 12mg / 14mg / 18mg / 20 mg and 24 mg Lenvatinib daily dosage oral capsules for a quantity of 30 to 90 capsules. The wholesale price of the injectable forms of Lenvatinib is quite high. To place an order at the lowest price and to get the best deal, buyers must get as many offers from sellers as they can. Lenvatinib can be purchased from a variety of Lenvatinib suppliers for a variety of prices.

Navigating our pharmaceutical marketplace

Being a global B2B pharmaceutical online marketplace, Pipelinepharma is structured to simplify pharmaceutical deals by providing you with an intuitive interface that is easy to engage with. The selection of Lenvatinib distributors offerings can be narrowed down with the use of filters and easily weighed against one another according to medication prices and commercial terms. The advanced filters help you filter out the countries for these substance manufacturers and this substance Lenvatinib suppliers that you are looking for. These also enable you to check the dossier status of this medicine and the GMP approvals of the different variants of Lenvatinib. Also, each manufacturer or supplier product description contains essential information about this substance including clinical data, stability zones, countries where Lenvatinib is already registered in. Manufacturers also have special, and delivery terms.

Establishing commercial ties

If you are a pharmaceutical licensing company or a distributor you can enter into deals or negotiations over these medicine offers with manufacturing companies after completing the free registration process and joining our online marketplace. This helps to ensure that you conclude the pharmaceutical product deal at a reasonable cost and achieve the best cost/benefit ratio for your company while bypassing lengthy sourcing, negotiation, and order process. Once you have finalized a deal, you can look forward to a long-lasting business relationship with the manufacturers Lenvatinib suppliers. This way, the marketplace allows you as a distributor to skip the process of shortlisting product manufacturers every time you are looking for in-licensing or distribution deals.

Quality Assurance

To keep up to the quality standards other than Good Manufacturing Practice approvals that this medicine manufacturers list has, we qualify their companies before they are onboarded on the platform. This allows us to screen Lenvatinib Manufacturers for the quality of the pharmaceutical products’ dossiers and protect against the risk of possible malpractices.